This trial is evaluating whether Tirzepatide will improve 2 primary outcomes and 9 secondary outcomes in patients with Obesity. Measurement will happen over the course of Baseline, Week 24.
This trial requires 700 total participants across 2 different treatment groups
This trial involves 2 different treatments. Tirzepatide is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
"Obesity is defined as a body mass index (BMI >30 kg/m(2)) that is accompanied by increased risks of heart disease, diabetes, sleep problems, high-blood pressure and osteoarthritis, among others. It is among the leading modifiable risk factors associated with a range of chronic diseases. In men, the greater BMI, it is more likely than the lack of it, for the occurrence of high blood pressure, diabetes, and cardiovascular diseases. The BMI is significantly correlated with hyperinsulinaemia and increased insulin resistance. This correlation is higher in girls and the obese children than in the rest of the population." - Anonymous Online Contributor
"While dietary, lifestyle, and behavioral interventions can help to minimize weight gain, there is not enough evidence to show that they can actually cure obesity. As a result, clinicians and patient advocates should focus their efforts on treatment of obesity as a single priority." - Anonymous Online Contributor
"In men, obesity is one of the leading risk factors for mortality. The most frequently used biomarkers (such as waist circumference, LDL-cholesterol and apolipoprotein B levels) as well as other potential new biomarkers (including leptin and inflammatory markers such as high sensitivity C-reactive protein) should be evaluated in further large prospective studies aiming at defining the most sensitive and specific biomarkers for obesity and the development of new diagnostic strategies." - Anonymous Online Contributor
"It is estimated that a baby will become diabetic in the United States every 18 seconds. Also, it is estimated that 2.7 million children and teenagers will develop eating disorders during a 5-year period. Obesity is one in every third child and it is believed to be the second most common chronic disease after childhood asthma. Obesity has received increasing attention in Western nations because of its association with chronic illnesses like hypertension and coronary artery disease." - Anonymous Online Contributor
"Obesity occurs due to alterations in energy balance, in which energy is more readily delivered to the adipose tissue than is required for use, whereas energy expenditure is generally reduced; however, in overweight individuals, the contribution of increased activity to adiposity may be greater than in leanness." - Anonymous Online Contributor
"Nearly 40% of people admitted to hospitals in the United States had an in-hospital episode of obesity or obesity-related obesity in 2006. The incidence of obesity and obesity-related diseases in the hospital has significantly decreased, while morbidity and mortality have increased. Obesity is a serious health problem; a large percentage of patients have serious comorbidities and are at risk for poor outcomes, including premature death. Given the substantial improvements in treating and preventing obesity, efforts should be made to educate patients and general practitioners on the health consequences of obesity and obesity-related problems." - Anonymous Online Contributor
"Tirzepatide 2.5 mg and 25 mg were superior to the placebo, but did not show superiority over the 100 μg formulation in achieving clinical improvement." - Anonymous Online Contributor
"The administration of tirzepatide was associated with a significant improvement in several HRQOL indices in those with obesity who are not considered candidates for bariatric surgery or restrictive dieting." - Anonymous Online Contributor
"In this exploratory study, tirzepatide in combination is well-tolerated in combination with other treatments. This clinical experience is consistent with the FDA's indication for the use of tirzepatide in combination with a balloon device in the treatment of patients with advanced gastrointestinal stromal tumors who have progression or complications following chemotherapy." - Anonymous Online Contributor
"Tirzepatripping is often overlooked while treating the patients with a variety of gastrointestinal and hepatobiliary conditions. Tirzepatidiomentous with pirfenidone appears to be an effective treatment of autoimmune hepatitis and liver fibrosis. Tirzepatization is also useful in the management of oesophagitis and oesophageal varices." - Anonymous Online Contributor
"Tirzepatide has a profound benefit of inducing tumour regression and reduces tumour size following its administration. The data have shown that these responses occur only in patients with the best prognostic factors including K-ras mutational status. Tirzepatide also shows a better response in K-ras (wt/wt) patients than in K-ras (wt/mutation) patients. Tirzepatide, therefore, may be especially useful for controlling a subset of patients who are treated with targeted therapy." - Anonymous Online Contributor
"It was efficacious in reducing %HbA1c in patients who had not achieved ≥7% or ≥8% HbA1c reduction at 48 weeks. While it is effective in patients with Type 2 diabetes, the side effects were usually tolerable, with no incidence of serious or life-threatening side effects." - Anonymous Online Contributor